Evidence map›Paper›PMID 39901166›Full record

ArticleMolecular cancer2025

SELP

Qingyu Huang, Wenhui Yang, Fuhao Wang, Rui Huang, Qian Wang, Xiaohui Li, Tianyu Lei, Shengqin Yue, Wenxue Zou, Qi An and 3 more

Abstract read
In one paragraph

Article in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Qingyu Huang *Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China.
Wenhui Yang *Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Fuhao Wang *Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China.
Rui Huang *Department of Oncology, Chongqing University Fuling Hospital, Chongqing, China.
Qian WangDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Xiaohui LiDepartment of Medical Oncology, Peking University First Hospital, Beijing, China.
Tianyu LeiDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Shengqin YueDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Wenxue ZouDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China.
Qi AnDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Jinbo YueDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China. jbyue@sdfmu.edu.cn.
Qinyong HuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China. rm001223@whu.edu.cn.
Chao LiuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China. charles.liu@whu.edu.cn.

Funding

Bethune Cancer Radiotherapy Translational Medicine Research Fund flzh202103National Natural Science Foundation of China 82272753National Natural Science Foundation of China 82403773Postdoctoral Fellowship Program of CPSF GZB20230041Shandong Provincial Natural Science Foundation ZR2021LZL002Shandong Provincial Natural Science Foundation ZR2021QH006The Key Research and Development Program of Shandong (Major Science & Technology Innovation Project) 2021SFGC05012021
6 · The paper itself

Abstract

P-selectin (SELP) expression in tumor cells has been implicated in promoting tumor progression and treatment resistance across various cancers. However, our prior study identified SELP expression in a specific subpopulation of endothelial cells within cervical cancer (CC) and potentially linked to anti-cancer immune response. The precise mechanisms by which SELP influences anti-cancer immunity and its involvement in radiotherapy response in CC, however, remain elusive. To address these gaps, this study analyzed tumor tissue samples from 205 CC patients undergoing radiotherapy, scRNA-seq data from 42,159 cells of eight patients, and bulk RNA-sequencing data from 187 radiotherapy-treated patients. The results revealed that elevated SELP expression in tumor endothelial cells (TECs) was significantly correlated with improved survival outcomes in patients treated with radiotherapy. The SELP

Indexed as

CD8-Positive T-LymphocytesCell CommunicationEndothelial CellsP-SelectinUterine Cervical NeoplasmsBiomarkers, TumorChemokine CCL5FemaleGene Expression Regulation, NeoplasticHumansLymphocytes, Tumor-InfiltratingPrognosisTumor MicroenvironmentBiomarkers, TumorChemokine CCL5P-Selectin

Identifiers

PMID39901166
PMCPMC11789365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.